
Andrew Zhuang Wang MD (He/Him)
Gastrointestinal Cancer, Urologic Cancer
A. Kenneth Pye Professor in Cancer Research Vice Chair of Translational Research and commercialization Department of Radiation Oncology UT Southwestern Medical Center
Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-8525
Fax+1 214-645-8526
Dr. Wang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2009
- Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 2004 - 2005
- Harvard Medical SchoolClass of 2004
Certifications & Licensure
- NC State Medical License 2009 - 2025
- TX State Medical License 2021 - 2025
- MA State Medical License 2006 - 2009
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Fellow American Society for Clinical Investigation, 2019
- Fellow The American Institute for Medical and Biological Engineering (AIMBE), 2018
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Join now to see all
Clinical Trials
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
- Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases Start of enrollment: 2009 Apr 01
- PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study Start of enrollment: 2012 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Tumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry.Hyesun Hyun, Bo Sun, Mostafa Yazdimamaghani, Albert Wielgus, Yue Wang
The Journal of Clinical Investigation. 2025-03-11 - Multiple sclerosis treatments a review of current biomedical engineering approaches.Sayyed Ourmazd Mohseni, Kin Man Au, Wadih Issa, Lifu Ruan, Olaf Stuve
Biomaterials. 2025-02-01 - Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy.Joyce Hwang, Eda Holl, Yuan Wu, Anika Agarwal, Mark D Starr
JCI Insight. 2025-01-07
Books/Book Chapters
Lectures
- Nanomedicine approaches to chemoradiationGordon Conference: Cancer Nanotechnology - 2013
- Plenary speaker: Reformulating failed drugs using nanoparticlesNational Cancer Institute Centers for Nanotechnology Excellence Principle Investigators Meeting - 2013
- Nanomedicine to improve chemoradiotherapyDartmouth College Cancer Nanotechnology Symposium: Immuno Targeting and Delivery - 2013
- Join now to see all
Other
- Drug delivery system for pharmaceuticals and radiationWang AZ, Farokhzad OC, Zhang LF, Radovic-Moreno A, Gu F, Langer R.
International PCT Patent Application No.: PCT/US08/082655 - Delivery for brachytherapy and associated methods.Wang Z, Werner M, Chen R, Byrne J, Karve S, Desimone J.
International PCT Patent Application No.: PCT/US2010/053357 - Novel Wortmannin Nanoparticles and Uses Thereof.Wang Z, Pacold M, Werner M, Karve S.
US PCT/US2011/ 61431689 - Join now to see all
Press Mentions
- UT Southwestern Develops Nanotherapeutic to Ward off Liver CancerJanuary 14th, 2022
- Researchers Study Strategies for Using Nanotechnology to Boost Cancer TherapeuticsApril 23rd, 2019
- Improved Capture of Cancer Cells Could Aid in Disease TrackingMarch 15th, 2018
Grant Support
- Tissue engineered organ-specific cancer metastasis model for cancer researchUT SOUTHWESTERN MEDICAL CENTER2024–2029
- Development of 3D organ-specific models of colorectal cancer metastasisNational Institutes of Health/National Cancer Institute2013–Present
- Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapyNational Institutes of Health/National Cancer Institute2013–Present
- Center for Cancer Nanotechnology ExcellenceNational Institutes of Health/National Cancer Institute2010–Present
- Development of nanoparticle formulations of DNA double-strand break repair inhibitors to improve chemoradiotherapyLung Cancer Research Foundation2012–2013
- Development of Nanoparticle-based Multiplex Multimodality Imaging Agents for the Specific and Sensitive Detection of CancerNational Academies of Science-Keck Futures Initiative Imaging Science2011–2013
- Multifunctional Targeted Theranostic Nanoparticles Delivering Gemcitabine Triphosphate and IndiumNational Institutes of Health2011–2012
- Particle Loaded Spacers for Prostate Cancer BrachytherapyUniversity of North Carolina Cancer Research Fund2010–2012
- Particle-loaded spacers for prostate cancer brachytherapyNational Institutes of Health/National Cancer Institute2010–2012
- Development of molecularly targeted nanoparticles for the delivery of radiosensitizersTriad Golfers Against Cancer2010–2011
Research History
- Postdoctoral FellowResearch Fellow, Robert Langer, D.Sc./Omid Farokhzad, M.D. HST/Harvard-MIT Center for Nanotechnology Excellence, Cambridge, MA2006 - 2009
Professional Memberships
- Member
- Member
- Member
- Member
Other Languages
- Chinese (Mandarin)
Industry Relationships
- Research Support, Varian2020 - Present
- Co-Founder and Board Member, Archimmune Therapeutics2019 - Present
- Co-founder and CEO, Capio Bioscience2014 - Present
- Research support, Accuray2015 - 2017
- Consultant, Cerulean Pharma2014 - 2016
- Consultant, Samyang Biopharmaceuticals, INCEvaluate nanoparticle formulation of docetaxelDisclosure: consulting fee2011 - 2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: